Clinical Trial Update: A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa [Phase 2]

View source ↗

Summary

Ongoing Phase 2 randomized trial evaluating the safety, reactogenicity, and immunogenicity of an mRNA-based Mpox vaccine candidate in Africa.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Monkeypox
• Orthopoxvirus Infection
• Smallpox

Drugs mentioned

• Mpox vaccine candidate (mRNA-based)

Snippet

Sponsor: BioNTech SE | Conditions: Mpox (Monkeypox), Smallpox | Phase 2 | Status: RECRUITING